{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-10T00:15:20.014Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-10. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-10. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-10, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"DYN\",\n  \"company\": \"Dyne Therapeutics, Inc.\",\n  \"investigation_summary\": \"Dyne is a clinical-stage neuromuscular biotech whose BLA submission on May 26 triggered the investigation's smart-money trigger. Director Brian Posner made two verified open-market P-code purchases totaling ~$70K at $18.21 and $16.94 in late May/early June — genuinely clustered within 14 days. Three other directors received stock-option grants (vesting 2027) on June 5, which are compensation instruments, not directional signals. The company has two near-term catalysts: z-rostudirsen BLA filed for DMD accelerated approval (decision expected Q1 2027), and ACHIEVE REC topline data due Q1 2027 for DM1. Valuation is binary-biased by definition — no FCF, pre-revenue — but the analyst consensus target of $38 implies ~114% upside from current levels. The main risk: share count was just doubled (200M→400M authorized) suggesting anticipated ATM dilution ahead of launch costs.\",\n  \"verdict\": \"promising\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"long_stock\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Dyne Therapeutics is a Waltham, MA-based clinical-stage company leveraging its FORCE platform (TfR1-mediated delivery via Fab-payload conjugates using PMO/ASO oligos and enzymes) to develop therapeutics for genetically driven neuromuscular diseases. Its two lead programs are z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy (exon 51 skipping, BLA submitted May 26, 2026 seeking accelerated approval, potential launch Q1 2027) and z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1, ACHIEVE REC fully enrolled June 3 with 71 participants; topline data due Q1 2027). Additional programs target FSHD and Pompe disease. The company had $972M in cash at year-end 2025 vs. ~$169M debt, sufficient runway into late 2026/early 2027 assuming current burn rates. Authorized shares were doubled from 200M to 400M at the June 5 annual meeting, signaling likely near-term equity capital raise via ATM.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [\n        {\n          \"insider\": \"Brian S. Posner\",\n          \"role\": \"Director\",\n          \"amount_usd\": 70420,\n          \"date\": \"2026-06-08\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264004/xslF345X06/ownership.xml\"\n        },\n        {\n          \"insider\": \"Brian S. Posner\",\n          \"role\": \"Director\",\n          \"amount_usd\": 36420,\n          \"date\": \"2026-05-26\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526245237/xslF345X06/ownership.xml\"\n        }\n      ],\n      \"insider_open_market_total_usd_90d\": 106840,\n      \"distinct_insider_buyers_90d\": 1,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 0,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-07-27\",\n      \"recent_eps_surprise_pattern\": \"4 consecutive positive EPS surprises: Q3 2025 +10.1%, Q4 2025 +4.4%, Q1 2026 +6.7%. Loss narrowing trend consistent.\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"BLA submission for z-rostudirsen in DMD exon 51 with request for Priority Review/Accelerated Approval — filed May 26, 2026; FDA decision anticipated Q1 2027\",\n          \"date_or_window\": \"Filed May 26, 2026; PDUFA expected ~Q1 2027\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/dyne-therapeutics-announces-submission-biologics-113000085.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"clinical\",\n          \"description\": \"ACHIEVE REC full enrollment (71 participants) — topline data due Q1 2027 for z-basivarsen in DM1; BLA targeted Q3 2027\",\n          \"date_or_window\": \"REC enrolled June 3, 2026; topline data expected Q1 2027\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/dyne-therapeutics-announces-completion-enrollment-113000616.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"clinical\",\n          \"description\": \"Phase III FORZETTO confirmatory trial initiated May 20, 2026 for z-rostudirsen in DMD exon 51 (90 participants, 72-week primary endpoint RFF velocity)\",\n          \"date_or_window\": \"Initiated May 20, 2026; enrollment ongoing\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/dyne-therapeutics-initiates-phase-3-123337727.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": null,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -4.21,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": null,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"Pre-revenue clinical biotech — traditional metrics inapplicable. Analyst consensus target of $38 vs. current price of ~$18 implies 114% upside. Risk/reward skewed toward BLA approval (Accelerated Approval pathway via dystrophin surrogate endpoint) given positive DELIVER trial data and FDA pre-BLA meeting alignment.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"B+\"\n    },\n    \"technical\": {\n      \"above_50dma\": false,\n      \"above_200dma\": true,\n      \"rsi_14\": 50.2,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 17.92,\n    \"ytd_return_pct\": 41.66,\n    \"from_52w_high_pct\": -28.32\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-03-02\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526084178/dyn-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 filed March 2, 2026; large accelerated filer status confirmed. Cash $972M vs. debt ~$169M at year-end 2025.\",\n        \"BLA for z-rostudirsen targeted Q2 2026 (actually submitted May 26 — on track).\",\n        \"FORZETTO Phase III aligned with FDA, planned initiation Q2 2026 (initiated May 20 — on track).\",\n        \"z-basivarsen BLA targeted Q3 2027; launch expected H1 2028. HARMONIA Phase 3 initiated March 2026.\",\n        \"Hercules loan agreement: $150M facility drawn in tranches starting June 27, 2025.\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-11\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526215702/dyn-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: R&D $77.3M, G&A $18.9M; net loss $(95.8M). Cash $753M + marketable securities $219M = ~$972M liquid.\",\n        \"Cash decreased from $893M (Dec 2025) to $753M (Mar 2026), reflecting ~$140M burn in Q1 — elevated but expected for late-stage trials.\",\n        \"Vendor financing arrangement of $6.2M recognized as debt-like obligation.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-08\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/dyn-20260605.htm\",\n      \"key_takeaways\": [\n        \"Annual meeting June 5, 2026: Authorized share count INCREASED from 200M to 400M. Certificate of amendment filed June 8.\",\n        \"Brian Posner re-elected with strong shareholder support (148.5M for vs. 0.54M withheld).\",\n        \"Says a lot about expected dilution needs ahead of launch preparation.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-03\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-20260603.htm\",\n      \"key_takeaways\": [\n        \"ACHIEVE REC fully enrolled: 71 participants. Topline data Q1 2027; BLA target Q3 2027 for accelerated approval.\",\n        \"Potential launch H1 2028 assuming Priority Review and FDA approval on timeline.\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-07-17\",\n      \"2026-09-18\",\n      \"2026-10-16\",\n      \"2026-12-18\"\n    ],\n    \"iv_summary\": \"ATM IV ~71-126% across expirations; July 17 ATM-ish strikes show IV in the 70-100%+ range. Elevated premium environment consistent with binary catalysts.\",\n    \"notable_skew_or_flow\": \"Put/call ratio extremely low at 0.06 (291 calls vs. 17 puts). Bullish directional bias confirmed by flow. Top OI on calls: $35 strike (254 contracts), suggesting covered-call or LEAP target buyers. No whale blocks detected — weak UOA signal.\"\n  },\n  \"competitive_landscape\": \"Dyne competes in DMD against Sarepta (eteplirsen, golodirsen), NS Pharma (viltolarsen), and others; in DM1 vs. small molecules targeting splicing. Dyne's FORCE platform differentiation is TfR1-mediated muscle/CNS delivery with modular payload approach — clinically validated across multiple programs.\",\n  \"key_risks\": [\n    \"Binary regulatory risk: BLA approval not guaranteed even with accelerated pathway; FDA may require more data\",\n    \"Cash burn ~$140M/quarter at current rate — runway into H2 2027 at most without additional capital raise\",\n    \"Authorized share increase to 400M signals anticipated significant dilution before/z-during launch preparation\",\n    \"No revenue, pre-commercial company entirely dependent on regulatory outcomes\",\n    \"DMD exon-skipping space is competitive; reimbursement and market penetration for z-rostudirsen uncertain even if approved\",\n    \"Technical: below 50DMA (17.92 vs. MA50=18.24); recent bearish MACD cross within 1 bar\"\n  ],\n  \"what_the_market_might_be_missing\": \"The May 26 BLA filing received limited coverage despite being a major regulatory milestone — z-rostudirsen could be the first TfR1-targeted exon-skipping DMD therapy seeking Accelerated Approval via dystrophin surrogate endpoint. Analyst consensus target of $38 vs. current ~$18 reflects significant upside if approved; the stock has pulled back ~28% from 52-week high, creating a better entry than October 2025's spike levels. Posner's consecutive open-market buys at $18.21 and $16.94 (below the analyst mean target) signal insider conviction.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"low_liquidity\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"BLA Submission Press Release\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/dyne-therapeutics-announces-submission-biologics-113000085.html\"\n    },\n    {\n      \"label\": \"ACHIEVE REC Enrollment 8-K / Press Release\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-20260603.htm\"\n    },\n    {\n      \"label\": \"Annual Meeting Results (Share Authorization Increase)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/dyn-20260605.htm\"\n    },\n    {\n      \"label\": \"Posner Form 4 Purchase June 5, 2026 ($16.94)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264004/xslF345X06/ownership.xml\"\n    },\n    {\n      \"label\": \"Posner Form 4 Purchase May 26, 2026 ($18.21)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1818794/000119312526245237/xslF345X06/ownership.xml\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-10T00:16:49.940Z",
      "raw_content": "<think>The dossier is for DYN (Dyne Therapeutics, Inc.), a clinical-stage neuromuscular biotech.\nLet's score it according to the rubric.\n\nA. SMART-MONEY CLUSTER (max 25)\n- 1 distinct insider buyer (Brian Posner, Director) with $106,840 total purchases in last 90 days.\n- CEO/CFO not buyers.\n- Total purchases < $500K threshold for 10 pts. So 0 pts here.\n- No notable 13F, politician buys.\n- Score: 0.\n\nB. OPTIONS FLOW / UOA (max 10)\n- IV is elevated (71-126%).\n- Put/call ratio extremely low (0.06), bullish flow, but \"No whale blocks detected — weak UOA signal.\"\n- Score: 0 (no whale blocks, no specific skew/flow points met).\n\nC. CATALYST (max 25)\n- Next earnings: 2026-07-27. Last 4 quarters EPS surprise > 0%? It says \"4 consecutive positive EPS surprises\". But it's a biotech, usually they report losses. The dossier says \"Loss narrowing trend consistent.\" This might be a hallucination by Scout or just accounting. Regardless, earnings within 90 days + positive surprises = 10 pts.\n- Pending product launch / FDA / contract milestone: BLA filed May 26, 2026. PDUFA Q1 2027. ACHIEVE REC topline Q1 2027. This is a major regulatory catalyst. 8 pts.\n- Recent guidance raise: true. 5 pts.\n- Quantifiable sector tailwind: none mentioned.\n- Cap at 25. Let's give 15 (10 for earnings, 5 for BLA milestone). Actually, BLA is a huge catalyst. I'll give 15.\n\nD. MISPRICING (max 15)\n- Forward P/E: null (pre-revenue).\n- EV/EBITDA: -4.21.\n- FCF yield: null.\n- SOTP gap: null.\n- Analyst target $38 vs $18 implies 114% upside. But traditional metrics inapplicable.\n- Score: 0.\n\nE. QUALITY (max 15)\n- ROIC: null.\n- Gross margin: null.\n- Net debt/EBITDA: null.\n- Balance sheet grade B+. Cash $753M + $219M MS = $972M. Debt $169M. Net cash ~$800M.\n- Score: 0 (no metrics provided, but balance sheet is strong. I'll give 0 for strict rubric compliance, or maybe 2 for net cash position? Rubric says 5 pts for net debt/EBITDA <= 2x or net cash. It has net cash. I'll give 5.)\n\nF. MOMENTUM/TECHNICAL (max 10)\n- Below 50DMA, above 200DMA.\n- RSI 50.2.\n- MACD bearish cross.\n- 12-1 momentum vs sector: null.\n- Score: 2 (RSI in 40-65 zone).\n\nTotal Score: 0 + 0 + 15 + 0 + 5 + 2 = 22.\nWait, let's re-evaluate Catalyst. Earnings in 47 days (July 27). 4 consecutive positive surprises. That's 10. BLA filed + PDUFA Q1 2027 is 8. Total 18. Cap 25. So 18.\nScore: ~25.\n\nRisk Class: market_cap not explicitly given, but clinical-stage biotech with $18 price and ~200M shares (doubled to 400M) implies market cap ~$3.6B. Actually, it says \"large accelerated filer status confirmed\". Usually >$750M. So it's likely >$5B or close to it. But clinical biotech before revenue is often \"asymmetric\" or \"core\" depending on cap. I'll assume core if >$5B, but the dossier says \"Authorized share count increased from 200M to 400M\". If price is $18, cap is ~$3.6B. I'll classify as \"asymmetric\" due to pre-revenue clinical stage, or \"core\" if it's actually >$5B. The prompt says risk class depends on market_cap field. It's missing from the JSON. I'll infer \"asymmetric\" or \"core\". Given it's a small/mid cap biotech, I'll lean \"asymmetric\" or just \"core\" if it's a large accelerated filer. Actually, large accelerated filer threshold is $700M public float. I'll stick with \"core\" if >$5B, but it's likely < $5B. I'll use \"asymmetric\" to be safe, or just \"core\" if I assume it's >$5B. Wait, the prompt says \"risk_class — choose one based on the dossier's market_cap field\". Since it's missing, I'll default to \"core\" for biotechs of this size, or \"asymmetric\". I'll go with \"core\" but note it's clinical stage. Actually, clinical-stage biotechs are inherently asymmetric. I'll use \"asymmetric\".\n\nAnti-Signals: \"dilution\", \"low_liquidity\".\nDilution: authorized shares doubled to 400M. This is a significant anti-signal for a pre-revenue company. It creates massive overhang.\nLow liquidity: likely.\nAnti-signal gate: \"Convertble/warrant overhang creating dilution > 10% of float\" - not exactly, but share count doubled is a dilution warning. The prompt says anti_signals_present is non-empty -> treat each as a gate; skip unless you can articulate WHY it doesn't apply.\nDilution is a major red flag for a clinical-stage biotech burning $140M/qtr. They will likely do an ATM offering soon. This destroys shareholder value.\nLow liquidity is also a risk.\n\nGiven the score (~25) and anti-signals (dilution, low liquidity), and the fact that it's a pre-revenue clinical biotech with binary risk and massive anticipated dilution, this strongly points to SKIP.\nThe dossier itself says: \"Authorized share increase to 400M signals anticipated significant dilution before/z-during launch preparation.\" and \"Cash burn ~$140M/quarter at current rate — runway into H2 2027 at most without additional capital raise\".\nThis is a classic \"cash burn + dilution overhang\" biotech. Not a good investment right now unless you're gambling on the binary event, but the anti-signal gate triggers a skip.\nAlso, score is well below 45.\nI will skip.\n\nLet's calculate scores carefully to match the rubric.\nA: 0 (only 1 insider, <$500k)\nB: 0 (no whale blocks, weak UOA)\nC: 15 (Earnings in 90d + positive surprises = 10; BLA milestone = 5. Cap 25)\nD: 0 (no metrics)\nE: 5 (Net cash position ~$800M)\nF: 2 (RSI 40-65)\nTotal: 22.\n\nReason for skip: Score is 22, well below the 45 threshold. The dossier flags significant anti-signals (anticipated dilution from the doubled share authorization and low liquidity) that, combined with the pre-revenue burn rate, create substantial overhang risk. The binary regulatory catalyst is priced into the elevated IV environment, and the lack of traditional valuation metrics or strong smart-money clustering makes this a speculative setup rather than a high-conviction thesis.\n\nI will output the skip JSON.\nCheck format:\n{\n  \"skip\": true,\n  \"score\": 22,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 2\n  },\n  \"reason\": \"Score of 22 falls well below the 45 threshold. Significant anti-signals (anticipated dilution from the doubled share authorization and low liquidity) combined with a pre-revenue burn rate create substantial overhang risk. The binary catalyst is already reflected in elevated IV, and the lack of traditional valuation metrics or broad insider buying makes this a speculative setup rather than a publishable thesis.\"\n}\n\nWait, let's verify the \"dilution\" anti-signal gate. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI can articulate that the dilution is a real risk (authorized shares doubled to 400M with $140M/qtr burn), so it applies. Skip is correct.\n\nOne minor thing: The prompt says \"risk_class — choose one based on the dossier's market_cap field\". It's missing, but I don't need it for a skip.\nI will produce the skip JSON exactly.\nCheck numbers: A=0, B=0, C=15, D=0, E=5, F=2. Sum=22.\nMatches rubric.\nReady. \nOutput matches requested format. No extra text.\nProceed. \nSelf-Correction/Refinement during thought: \nCould I give it a higher score? \nCatalyst: Earnings in 47 days (July 27) + 4 positive surprises = 10. BLA filed + PDUFA Q1 2027 = 8. Total 18. I'll use 18.\nQuality: Net cash position = 5.\nTechnical: RSI 40-65 = 2.\nTotal = 25. Still < 45.\nSkip is robust.\nI will output the JSON. \nAll constraints met. \nProceeds. \nOutput Generation. \n```json\n{\n  \"skip\": true,\n  \"score\": 25,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 2\n  },\n  \"reason\": \"Score of 25 falls well below the 45 threshold. The dossier flags material anti-signals (anticipated dilution from the doubled share authorization and low liquidity) that, combined with a ~$140M/quarter burn rate, create substantial overhang risk. The binary catalyst is already reflected in elevated IV, and the lack of traditional valuation metrics or broad insider buying makes this a speculative setup rather than a publishable thesis.\"\n}\n```\nWait, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will remove the markdown fences.\nCheck score breakdown sum: 0+0+18+0+5+2 = 25. Correct.\nReason matches guidelines.\nDone. \nProceeds. \nOutput matches exactly. \n(Self-Correction/Verification during drafting)\nLet's double check the catalyst scoring. \"10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\". Dossier says next earnings 2026-07-27 (within 90 days). \"4 consecutive positive EPS surprises\". So 10 pts.\n\"8 pts: pending product launch / FDA / contract milestone in horizon\". BLA filed May 26, PDUFA Q1 2027. So 8 pts.\nTotal catalyst = 18. Cap 25. Correct.\nQuality: \"5 pts: net debt / EBITDA ≤ 2x (or net cash)\". Dossier says Cash $753M + MS $219M = $972M vs Debt $169M. Net cash. So 5 pts. Correct.\nTechnical: \"2 pts: RSI 14 in 40-65 zone\". RSI is 50.2. So 2 pts. Correct.\nSmart Money: 1 distinct buyer, <$500k. 0 pts.\nOptions: No whale blocks. 0 pts.\nMispricing: null. 0 pts.\nTotal: 25.\nSkip is definitive.\nOutput matches.\nProceeds. \nFinal JSON generation. \n(Note: I will ensure no markdown code blocks are used as per strict instruction \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\")\nReady. \nOutput matches response. \n[Done]\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 25,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 2\n  },\n  \"reason\": \"Score of 25 falls well below the 45 threshold. The dossier flags material anti-signals (anticipated dilution from the doubled share authorization and low liquidity) that, combined with a ~$140M/quarter burn rate, create substantial overhang risk. The binary catalyst is already reflected in elevated IV, and the lack of traditional valuation metrics or broad insider buying makes this a speculative setup rather than a publishable thesis.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 25,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 2\n  },\n  \"reason\": \"Score of 25 falls well below the 45 threshold. The dossier flags material anti-signals (anticipated dilution from the doubled share authorization and low liquidity) that, combined with a ~$140M/quarter burn rate, create substantial overhang risk. The binary catalyst is already reflected in elevated IV, and the lack of traditional valuation metrics or broad insider buying makes this a speculative setup rather than a publishable thesis.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 25,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 2\n  },\n  \"reason\": \"Score of 25 falls well below the 45 threshold. The dossier flags material anti-signals (anticipated dilution from the doubled share authorization and low liquidity) that, combined with a ~$140M/quarter burn rate, create substantial overhang risk. The binary catalyst is already reflected in elevated IV, and the lack of traditional valuation metrics or broad insider buying makes this a speculative setup rather than a publishable thesis.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 89926,
  "stop_reason": "stop",
  "completed_at": "2026-06-10T00:16:49.940Z"
}